Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study

Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima, Ryosuke Goto, Richuan Zheng, Hidemi Nakagawa
  • The Journal of Dermatology, June 2018, Wiley
  • DOI: 10.1111/1346-8138.14504
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Hiroshi Kubo